*Serial sampling of ctDNA detected day 28 post-surgery, after day 28 post-surgery prior to recurrence, and at recurrence increased sensitivity by up to 45% vs a single post-surgery.
†100% of patients were able to undergo evaluation without the need for tissue testing; 96% of all samples passed QC metrics
1. Nakamura Y. Tsukada Y. Matsuhashi N, et al. Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay. Clin Cancer Res. 2024.
Guardant Reveal was developed as Laboratory Developed Tests (LDTs) and its performance characteristics determined by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. The test has not been cleared or approved by the US FDA or by EU/UK Notified Body.
Product availability may vary depending on country / region. Guardant Reveal is not approved nor marketed in the EU.